Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
R-Pharm
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants with metastatic breast cancer
Measurable disease
Up to 1 chemotherapy regimen is acceptable. Participants who have received paclitaxel in the neoadjuvant or adjuvant setting acceptable, only if the last dose of paclitaxel was received 12 months or less before the treatment. There is no timeframe for prior paclitaxel in the metastatic setting.
Human epidermal growth factor receptor 2-positive participants allowed if they have progressed after receiving treatment with trastuzumab or lapatinib
Eastern Cooperative Oncology Group Performance status of 0-1
Age younger than 18 years
Women of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study and for at least 4 weeks after the last dose of investigational products
You may not be if
More than 1 chemotherapy regimen for the treatment of metastatic breast cancer
Prior treatment with any epothilone, capecitabine, or docetaxel
Prior radiation must not have included 30% or more of major bone marrow-containing areas (pelvis, lumbar spine). If prior radiation was less than 30%, a minimum interval of 2 weeks must be allowed between the last radiation treatment and administration of study medication. There must be at least 1 week between focal/palliative radiation and administration of study medication.
Any current or previous history of brain and/or leptomeningeal metastases
Neuropathy greater than Grade 2
Any concurrent malignancy other than nonmelanoma skin cancer or carcinoma in situ of the cervix
Uncontrolled diabetes mellitus
Chronic hepatitis
HIV-positive status
Administration of trastuzumab, lapatinib, bevacizumab, or other systemic treatment for cancer must be discontinued 28 days prior to study medication. Hormonal anticancer agents must be discontinued at least 14 days prior to study medication. Hormonal replacement therapy is acceptable
Biphosphonates for palliation of bone metastases allowed if initiated at least 7 days before study entry
